Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.4x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 18 Aug 2026	US$1.5t	US$173.0b	-US$20,925,261,734.52	16.7x	-69.4x	8.4x
Thu, 16 Jul 2026	US$1.4t	US$169.8b	-US$12,328,877,587.59	17.4x	-113.4x	8.2x
Sat, 13 Jun 2026	US$1.3t	US$170.0b	-US$12,155,057,640.59	16.5x	-105.2x	7.5x
Mon, 11 May 2026	US$1.3t	US$170.4b	-US$11,823,943,233.31	17.7x	-109.5x	7.6x
Wed, 08 Apr 2026	US$1.3t	US$166.2b	-US$11,886,970,549.87	16.2x	-108.1x	7.7x
Fri, 06 Mar 2026	US$1.3t	US$169.6b	-US$14,151,126,071.96	21.2x	-94.5x	7.9x
Sun, 01 Feb 2026	US$1.3t	US$163.6b	-US$15,076,774,528.41	20.3x	-83.2x	7.7x
Tue, 30 Dec 2025	US$1.2t	US$163.6b	-US$15,689,132,019.66	21.9x	-78.7x	7.5x
Thu, 27 Nov 2025	US$1.2t	US$163.6b	-US$16,203,897,081.55	19.1x	-76.4x	7.6x
Sat, 25 Oct 2025	US$1.2t	US$163.4b	-US$18,534,573,619.10	17.3x	-62.5x	7.1x
Mon, 22 Sep 2025	US$1.1t	US$163.5b	-US$18,307,901,758.97	16.3x	-59.2x	6.6x
Wed, 20 Aug 2025	US$1.1t	US$163.6b	-US$18,817,514,396.75	16.8x	-56.9x	6.5x
Fri, 18 Jul 2025	US$983.5b	US$155.7b	-US$23,413,712,907.26	16.5x	-42x	6.3x
Sun, 15 Jun 2025	US$949.1b	US$155.9b	-US$23,959,829,667.00	16.3x	-39.6x	6.1x
Tue, 13 May 2025	US$865.3b	US$155.1b	-US$24,600,766,978.05	16.9x	-35.2x	5.6x
Thu, 10 Apr 2025	US$704.8b	US$118.6b	-US$36,908,648,987.19	21.5x	-19.1x	5.9x
Sat, 08 Mar 2025	US$845.1b	US$119.0b	-US$37,271,574,129.99	17.2x	-22.7x	7.1x
Mon, 03 Feb 2025	US$1.0t	US$149.5b	-US$26,306,804,829.57	17.2x	-38.1x	6.7x
Wed, 01 Jan 2025	US$960.8b	US$149.6b	-US$26,363,797,961.52	16.9x	-36.4x	6.4x
Fri, 29 Nov 2024	US$1.0t	US$150.0b	-US$26,596,552,206.01	16.6x	-39.1x	6.9x
Sun, 27 Oct 2024	US$888.6b	US$113.1b	-US$36,033,068,263.01	20.6x	-24.7x	7.9x
Tue, 24 Sep 2024	US$920.0b	US$113.2b	-US$35,983,947,157.41	21.9x	-25.6x	8.1x
Thu, 22 Aug 2024	US$903.8b	US$113.2b	-US$35,868,195,932.56	23.3x	-25.2x	8x
Sat, 20 Jul 2024	US$1.2t	US$164.5b	-US$28,047,850,966.89	29x	-42.5x	7.3x
Mon, 17 Jun 2024	US$1.2t	US$164.4b	-US$27,941,797,208.37	27.3x	-41.4x	7x
Wed, 15 May 2024	US$1.1t	US$164.6b	-US$27,141,970,719.54	27.5x	-41.5x	6.8x
Fri, 12 Apr 2024	US$1.1t	US$164.3b	-US$23,380,537,394.48	21x	-48x	6.8x
Sun, 10 Mar 2024	US$1.2t	US$167.3b	-US$22,140,783,177.03	19x	-53.9x	7.1x
Tue, 06 Feb 2024	US$1.3t	US$196.1b	-US$18,610,955,456.92	17.5x	-70.8x	6.7x
Thu, 04 Jan 2024	US$1.4t	US$204.8b	-US$22,306,519,032.00	20.9x	-63.4x	6.9x
Sat, 02 Dec 2023	US$1.3t	US$204.7b	-US$22,044,035,456.00	19x	-56.7x	6.1x
Mon, 30 Oct 2023	US$1.2t	US$206.6b	-US$15,116,353,891.00	16.3x	-78x	5.7x
Wed, 27 Sep 2023	US$1.3t	US$207.4b	-US$12,903,835,924.00	17.2x	-98.3x	6.1x
Fri, 25 Aug 2023	US$1.3t	US$207.6b	-US$12,461,259,012.00	17.3x	-102.1x	6.1x


US Market	0.11%
Healthcare	-0.86%
Biotech	0.59%
Biotech	0.59%

Company	Last Price	7D	1Y	Valuation
GILD Gilead Sciences	US$138.92	4.4% +US$7.3b	17.7%	PS5.7x
ABBV AbbVie	US$250.33	1.0% +US$4.2b	21.2%	PE70.6x
MRNA Moderna	US$64.46	7.8% +US$1.9b	129.5%	PS11.6x
AMGN Amgen	US$419.38	0.5% +US$1.2b	43.3%	PE25.9x
RVMD Revolution Medicines	US$212.00	2.4% +US$1.1b	481.6%	PB17.4x

Announcement • Aug 13

Neurocrine Biosciences Publishes Kinect-Pro Phase 4 Study Results Demonstrating Ingrezza Capsules Improve Patient-Reported Quality of Life and Functionality for People Living with Tardive Dyskinesia

Neurocrine Biosciences, Inc. announced publication of the KINECT-PRO Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA (valbenazine) capsules resulted in substantial and sustained improvements in patient-reported quality of life and functionality, alongside improvements in clinician-rated tardive dyskinesia (TD) movement severity. Improvements were observed regardless of underlying psychiatric diagnosis or baseline TD movement severity, including among participants with clinician-rated mild TD movements. KINECT-PRO is currently the only study to assess the effects of a vesicular monoamine transporter 2 (VMAT2) inhibitor (INGREZZA) on quality of life and functionality using multiple validated patient-reported outcomes (PROs), including the Tardive Dyskinesia Impact Scale (TDIS). TDIS, developed by Neurocrine Biosciences in partnership with thought leaders in neurology and psychiatry, is a unique, psychometrically validated tool that measures the impact and burden of TD from a patient's perspective. Together with clinician-rated assessments, these findings provide a more comprehensive understanding of how treatment may affect both TD movements and the impact of the disease on patients' daily lives. The primary endpoints of KINECT-PRO were changes from baseline to Week 24 in three validated patient-reported measures of quality of life and functionality, including: TDIS: Measures the physical, social and emotional impacts of TD; EuroQoL Visual Analogue Scale (EQ-VAS): Measures patients' self-rated overall health status; The Sheehan Disability Scale (SDS): Measures patient-reported functional impairment in work/school, social life and family/home life. Secondary endpoints evaluated clinician- and patient-reported changes in TD severity using the Abnormal Involuntary Movement Scale (AIMS), the Patient Global Impression of Change (PGI-C) and the Clinical Global Impression of Severity-TD (CGI-TD-S). Fifty-nine patients were enrolled in the KINECT-PRO study and received once-daily INGREZZA (40 mg, 60 mg or 80 mg) for up to 24 weeks. At baseline, approximately 41% of patients (24/59) had clinician-rated mild TD movement severity, while approximately 59% (35/59) had clinician-rated moderate or severe TD movement severity. Approximately 46% of patients (27/59) had schizophrenia or schizoaffective disorder, and approximately 54% (32/59) had major depressive disorder or bipolar disorder. Fifty-two patients completed the Week 24 visit. KINECT-PRO participants experienced substantial improvements across the three validated patient-reported measures of quality of life (TDIS, SDS and EQ-VAS), as well as improvements in clinician-reported TD severity. Mean improvements in TD impact (TDIS) and movement severity (AIMS) exceeded established minimal clinically important difference (MCID) thresholds as early as Week 8 and Week 4, respectively, and were sustained to Week 24. Improvements were observed regardless of underlying psychiatric condition or TD movement severity at baseline. Even patients with milder clinician-rated TD movement severity were impacted by TD at baseline and experienced clinically meaningful improvements by Week 24, including a -6.8 mean change from baseline in TDIS and a -5.6 mean change from baseline in AIMS. Approximately 58% of patients (26/45) met the threshold for TD symptomatic remission at Week 24, defined as a movement severity score of 0 ('none') or 1 ('minimal') in each of the seven body regions assessed by AIMS. Safety and tolerability of treatment were consistent with the known profile of INGREZZA, with no new concerns identified. Mean Change from Baseline at Week 24: TDIS (MCID -4), SDS - Social Life, SDS - Family Life, EQ-VAS, AIMS Total Score (MCID -2). Overall Population: -8.0, -2.3, -1.6, +13.1, -6.8 (n=45). Mild TD Subgroup: -6.8, -1.8, -1.3, +12.8, -5.6 (n=20). Moderate/Severe TD Subgroup: -8.9, -2.8, -1.8, +13.3, -7.8 (n=25). 52/59 (88%) completed the Week 24 visit; 45 were included for efficacy analyses. A decrease in score indicated improvement. An increase in score indicated improvement. The KINECT-PRO Phase 4, open-label study was designed to evaluate patient-reported outcomes on the use of INGREZZA (valbenazine) capsules in a tardive dyskinesia (TD) patient population reflective of real-world clinical practice. Participants had at least mild TD, were aware of and experiencing at least mild distress from their abnormal, involuntary movements and had a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or major depression. The KINECT-PRO study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic and clinical characteristics of the participants were broadly similar to those of the KINECT 3 and KINECT 4 studies. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale (TDIS). The TDIS is the only patient-reported outcome instrument designed for and psychometrically validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. The Tardive Dyskinesia Impact Scale (TDIS) is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. It was developed by Neurocrine Biosciences in partnership with thought leaders in neurology and psychiatry from qualitative studies and Phase 3 trials of INGREZZA for the treatment of TD (KINECT 3 and KINECT 4) as a comprehensive measure of impact and burden of TD from a patient's perspective. The TDIS consists of 11 questions evaluating physical and socio-emotional impact. Six scales are assessed: mouth/throat, dexterity, mobility, pain, social and emotional. The TDIS allows people with TD to rate how their symptoms affect daily activities and how their uncontrollable movements make them feel.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

AbbVie Lifts Guidance After Boey Wins EU Approval and Q1 Results Impress

Gilead Sciences Secures Appeals Court Win Blocking Import of Overseas HIV Drugs

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $390 million.

Insider notifies of intention to sell stock

Summit Therapeutics and Arcus Launch Major Renal Cancer Trial with Ivonescimab Combination

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

KYMR: Early BROADEN2 Completion Will Bring Atopic Dermatitis Catalyst Forward

Neurocrine Biosciences Publishes Kinect-Pro Phase 4 Study Results Demonstrating Ingrezza Capsules Improve Patient-Reported Quality of Life and Functionality for People Living with Tardive Dyskinesia

Consensus revenue estimates increase by 29%, EPS downgraded

ALNY: TTR Franchise And Pipeline Progress Will Support Future Stock Repricing

UTHR: Transplant Platform And Organ Manufacturing Advances Will Drive Future Stock Upside

MRNA: Future Upside Will Hinge On New Flu Vaccine Rollout

Here's Why We're Watching Obsidian Therapeutics' (NASDAQ:OBX) Cash Burn Situation

INSM: Respiratory Franchise Execution Will Outweigh Index Removal And Launch Concerns

IMVT: Future Autoimmune Indications Will Support Confidence In Long Term Earnings Outlook